Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Bharat Vaswani"'
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-5 (2021)
Abstract Background Chemotherapy induced nausea- vomiting (CINV) is considered as the most common, feared and most troublesome side effect of chemotherapy. NEPA (NEtupitant 300 mg + PAlonosetron 0.50 mg) is the first commercially available oral fixed
Externí odkaz:
https://doaj.org/article/bd27045ca3a24b8dbb05554950d05d0c
Autor:
Bharat Vaswani, Palanki S Dattatreya, Hanmant Barkate, Sagar B Bhagat, Saiprasad Patil, Amit Y Jadhav
Publikováno v:
Cureus. 14(9)
Background Female gender, young age, first chemotherapy cycle, and low alcohol intake have all been linked to an increased risk of nausea and vomiting from chemotherapy. We intended to see if netupitant and palonosetron (NEPA) could prevent chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::068b3490bc24da2a6dd6d5c89ea0d28b
https://pubmed.ncbi.nlm.nih.gov/36259011
https://pubmed.ncbi.nlm.nih.gov/36259011
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-5 (2021)
BMC Cancer
BMC Cancer
Background Chemotherapy induced nausea- vomiting (CINV) is considered as the most common, feared and most troublesome side effect of chemotherapy. NEPA (NEtupitant 300 mg + PAlonosetron 0.50 mg) is the first commercially available oral fixed-dose com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c08d126de349e77ed8c1011fde87d215
https://doaj.org/article/bd27045ca3a24b8dbb05554950d05d0c
https://doaj.org/article/bd27045ca3a24b8dbb05554950d05d0c
Publikováno v:
World Journal of Clinical Oncology
Background A new, oral fixed dose combination of highly selective neurokinin-1 receptor antagonist, netupitant with 5HT3 receptor antagonist, netupitant and palonosetron (NEPA) was approved in India for prevention of chemotherapy induced nausea and v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc42c4d0d4c2b6082319dc600c01e353
https://pubmed.ncbi.nlm.nih.gov/32879847
https://pubmed.ncbi.nlm.nih.gov/32879847
Publikováno v:
Indian Journal of Nephrology. 32:390
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::655b96b6109b94d4051db6885c51af28
https://doi.org/10.4103/ijn.ijn_101_22
https://doi.org/10.4103/ijn.ijn_101_22
Autor:
Narayanankutty Warrier, Vijay Patil, Adwaita Gore, Govind Babu, Shekhar Patil, Nirmal Vivek Raut, Kumar Prabhash, Nitesh Rohatgi, Amish Vora, Bharat Bhosale, Shailesh Arjun Bondarde, Vanita Noronha, T. P. Sahoo, Sewanti Limaye, Bharat Vaswani, Ullas Batra
Publikováno v:
Cancer Research, Statistics, and Treatment. 4:279
The management of patients with advanced non-small-cell lung cancer (NSCLC) is becoming increasingly complex, with the identification of driver mutations/rearrangements and the development and availability of appropriate targeted therapies. In 2018,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::297658cfd110504aefe9362f3205580f
https://doi.org/10.4103/crst.crst_61_21
https://doi.org/10.4103/crst.crst_61_21
Publikováno v:
Indian Journal of Medical and Paediatric Oncology. 29:59-61
Primary non-Hodgkin′s lymphoma (NHL) of the oral region is rare. Oral manifestations are present in 3-5% of cases of NHL and oral lesions are rarely the initial manifestation. We describe a 40 year old male who presented with a mass lesion primaril
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4000c09369d50f398a9fd4ae01f732c0
https://doi.org/10.4103/0971-5851.51448
https://doi.org/10.4103/0971-5851.51448
Publikováno v:
Indian Journal of Critical Care Medicine. Oct-Dec2004, Vol. 8 Issue 4, p225-225. 1/2p.